What Is Melanocortin? Definition and What Research Reports

Plain definition

Melanocortin is the collective name for a small family of peptide hormones that are all cut out of one large parent protein, and for the receptors those peptides act on. The parent protein is called proopiomelanocortin, usually shortened to POMC. Enzymes slice POMC into several finished peptides, including adrenocorticotropic hormone (ACTH) and the melanocyte-stimulating hormones known as α-MSH, β-MSH and γ-MSH. Together these peptides plus their five receptors (MC1R through MC5R) are described in the literature as the melanocortin system. The name comes from two of the earliest recognised functions: melano- for skin pigmentation and -cortin for stimulation of the adrenal cortex. A review of the system described it as a set of ligands, receptors, accessory proteins and endogenous antagonists acting across pigmentation, adrenal function, energy homeostasis, and other tissues (PMID 12556347).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question. Nothing here describes how any substance should be used.

The term in biochemical and regulatory terms

Biochemically, melanocortins are short peptides that share a common core sequence — His-Phe-Arg-Trp — which is the portion that engages the receptor. Because they all originate from POMC, their sequences overlap, and a single precursor can yield peptides with very different downstream roles depending on which enzymes process it in which tissue. A review of POMC evolution traced the precursor and its cleavage products across vertebrate lineages and described how the gene and its processing arose and diversified (PMID 31421696). Comparative work in fish similarly catalogued melanocortin ligands, receptors and accessory proteins in teleosts, reporting that the system is conserved but that receptor numbers and roles differ between species (PMID 21208603).

The five receptors are G protein-coupled receptors. In broad terms as described in the literature:

An unusual feature of this family is that it has endogenous antagonists — agouti and agouti-related peptide — which block receptor signalling rather than merely competing weakly. The 2003 review characterised this agonist/antagonist arrangement as a distinguishing property of the melanocortin system relative to most peptide hormone families (PMID 12556347). Receptor behaviour is also shaped by accessory proteins: a 2025 study reported that MRAP2 modified both the signalling profile and the oligomerisation state of the melanocortin-4 receptor (PMID 40998819).

How the term is used in peptide research

In research writing, "melanocortin" is almost always used as a category word. Papers refer to the melanocortin system, melanocortin signalling, melanocortin receptor agonists, or the central melanocortin pathway. Individual molecules get their own names — α-MSH, ACTH, or specific synthetic analogues — and the umbrella term is reserved for the shared machinery.

Energy balance and the central pathway

The largest body of literature concerns the hypothalamic circuit in which POMC neurons release melanocortin peptides that act on MC4R-expressing neurons. A 2023 review in Nature Reviews Endocrinology examined this central melanocortin system as a target in metabolic disorders, summarising receptor biology, genetic variation and pharmacological approaches (PMID 37365323). Mechanistic work has continued to add detail. A 2024 Cell Metabolism paper reported that primary cilia on MC4R-bearing neurons shortened with age and described this ciliary change as obesogenic (PMID 38452767). A 2022 study reported that the Elongator complex regulated the melanocortin satiety pathway (PMID 35537288), and a 2025 preprint reported that melanocortin-responsive Kiss1 neurons in the arcuate nucleus drove energy expenditure through glutamatergic signalling to the dorsomedial hypothalamus (PMID 40666856).

Inflammation and immunity

A separate literature treats melanocortins as regulators of immune responses. A 2019 review in Frontiers in Endocrinology surveyed melanocortin regulation of inflammation across receptor subtypes and tissues (PMID 31649620). In an animal model, researchers reported that melanocortin receptor agonists suppressed experimental autoimmune uveitis (PMID 35196505). These are preclinical and mechanistic findings, not statements about outcomes in people.

Cardiovascular and autonomic roles

More recent work has examined melanocortin signalling outside the classic appetite frame. A 2025 Circulation Research study reported that the melanocortin system activated carotid body arterial chemoreceptors in hypertension (PMID 40874981). A 2024 review discussed the brain leptin–melanocortin pathway as a research target in heart failure (PMID 39612121).

Where the term is misused

Several recurring errors appear in non-academic peptide discussion:

• Treating "melanocortin" as one drug. It is a family name covering multiple endogenous peptides and five receptors. A claim about "melanocortin" without naming a ligand and a receptor is too vague to be checked against any paper.
• Collapsing receptor subtypes. MC1R, MC3R, MC4R and MC5R are associated with different tissues and outputs in the reviewed literature (PMID 12556347). A finding at one receptor does not transfer to another.
• Reading rodent circuit findings as human outcomes. Papers on hypothalamic cilia, Elongator, or Kiss1 neurons describe mechanisms in laboratory models (PMID 38452767, PMID 40666856).
• Confusing precursor with product. POMC is the precursor protein; melanocortins are among its cleavage products (PMID 31421696).
• Ignoring accessory proteins. Receptor output can depend on partners such as MRAP2, which was reported to alter MC4R signalling and oligomerisation (PMID 40998819).

Related terms

• POMC (proopiomelanocortin) — the precursor protein from which melanocortins are cleaved.
• α-MSH, β-MSH, γ-MSH — melanocyte-stimulating hormones, individual melanocortin peptides.
• ACTH — adrenocorticotropic hormone, a melanocortin acting principally at MC2R.
• MC1R–MC5R — the five melanocortin receptors.
• AgRP / agouti — endogenous antagonists at melanocortin receptors.
• MRAP1 / MRAP2 — melanocortin receptor accessory proteins.
• Leptin–melanocortin pathway — the upstream hormonal input to hypothalamic POMC neurons.

Safety and adverse events: What Studies Report

The verified papers summarised on this page are mechanistic studies, animal experiments and reviews of receptor biology; they characterise signalling, circuits and pharmacological targets rather than reporting safety outcomes in human volunteers. The 2023 review discussed the central melanocortin system as a therapeutic target and the pharmacological considerations involved (PMID 37365323), and the 2019 inflammation review described receptor-specific effects across tissues (PMID 31649620). No dose, tolerability or adverse-event figures are stated here because none appear in the scope of the cited abstracts. Readers evaluating any specific melanocortin-targeting compound should look to that compound's own regulatory labelling and trial record rather than to the family-level literature.

Why the definition matters

Because melanocortin signalling touches pigmentation, steroid output, appetite, immune tone and autonomic control, the same word can appear in papers with almost no overlap in subject matter. Precision about which peptide, which receptor, which species and which tissue is what makes a melanocortin claim checkable. Reviews spanning evolution (PMID 31421696) and comparative physiology (PMID 21208603) illustrate how far the family's roles diverge across biology.

References

• The melanocortin system (American Journal of Physiology. Endocrinology and Metabolism, 2003)
• Evolution of proopiomelanocortin (Vitamins and Hormones, 2019)
• Fish melanocortin system (European Journal of Pharmacology, 2011)
• MRAP2 modifies the signaling and oligomerization state of the melanocortin-4 receptor (Nature Communications, 2025)
• Targeting the central melanocortin system for the treatment of metabolic disorders (Nature Reviews Endocrinology, 2023)
• Age-related ciliopathy: Obesogenic shortening of melanocortin-4 receptor-bearing neuronal primary cilia (Cell Metabolism, 2024)
• Elongator regulates the melanocortin satiety pathway (Biochemical and Biophysical Research Communications, 2022)
• Melanocortin-responsive Kiss1 neurons of the arcuate nucleus drive energy expenditure through glutamatergic signaling to the dorsomedial hypothalamus (bioRxiv, 2025)
• Melanocortin Regulation of Inflammation (Frontiers in Endocrinology, 2019)
• Melanocortin receptor agonists suppress experimental autoimmune uveitis (Experimental Eye Research, 2022)
• Melanocortin System Activates Carotid Body Arterial Chemoreceptors in Hypertension (Circulation Research, 2025)
• Targeting the Brain Leptin-Melanocortin Pathway to Treat Heart Failure (Current Hypertension Reports, 2024)